A balance between tissue-destructive and tissue-protective immunities: A role of toll-like receptors in regulation of adaptive immunity

Селедцов, В. И.; Селедцова, Г. В.

doi:10.1016/j.imbio.2011.10.011

Cited by 36 publications

(25 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IL-4 is known to be produced by Th2 T cells and is involved in Ab responses, as well as in dampening immune responses mediated by Th1 cells [14]. Therefore, the data obtained in this report suggest that Epo is able to directly down-regulate Th1 T cell activity and concomitantly up-regulate the activity of Th2 T cells.…”

Section: Discussionmentioning

confidence: 54%

See 1 more Smart Citation

Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes

Тодосенко

Shmarov

Малащенко

et al. 2016

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 54%

“…IFN-γ plays a pivotal role in immune reactivity mediated by Th1 cells [14]. Here we demonstrated that Epo could furnish a direct suppressive effect on IFN-γ production.…”

Section: Discussionmentioning

confidence: 60%

Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes

Тодосенко

Shmarov

Малащенко

et al. 2016

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

“…TLR2/6 agonist MALP-2 has been demonstrated to promote re-endothelialization and inhibits neointima formation after vascular injury via enhanced proliferation and migration of endothelial cells [33]. Accumulating data suggest that ligation of intracellular TLRs by endogenous ligands released from necrotic cells may result in developing Th2-like responses, as well as in the alternative activation of macrophages (M2), that favor local tissue protection and compensatory cell growth [34]. Additionally, an increase in gramnegative bacteria in reflux esophagitis can alter gene expression of pro-inflammatory cytokines via activation of the TLR3 and 4 [35,36].…”

Section: Discussionmentioning

confidence: 99%

Co-upregulation of Toll-like receptors 2 and 6 on peripheral blood cells in patients with obstructive sleep apnea

Chen

Liou

et al. 2015

Sleep Breath

View full text Add to dashboard Cite

show abstract

“…It is believed that IFNc-producing T-cells promote MS development (Gutcher & Becher 2007;Mannie & Curtis 2013;Seledtsov et al 2010) whereas T-cell formation of IL-4 could exert a neuroprotective effect (Seledtsov & Seledtsova 2012). The current study evaluated the frequencies of T-cells able to produce IFNc/IL-4 in samples from 12 healthy subjects (5 males, 7 females; average age 33 years) and in 10 MS patients (3 males, 7 females; average age 39 years).…”

Section: Immune Responses To T-cell Vaccinationmentioning

confidence: 91%

Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosis

Селедцова

Ivanova

Shishkov

et al. 2016

Journal of Immunotoxicology

View full text Add to dashboard Cite

The overall objective of disease management in autoimmune diseases is to suppress chronic inflammation and prevent organ damage. Therapies often revolve around five drug classes: non-steroidal antiinflammatory drugs (NSAIDS), anti-malarials, steroids, immunosuppressants, and bio-therapies. However, none of these is a 'cure' and each displays a potential for adverse events. In particular, while all of them suppress harmful autoimmune responses, they also impact on useful protective immune responses. T-Cell receptor (TCR) immunogenicity provides a rationale for T-cell vaccinations to induce anti-idiotypic immune responses with the purpose of down-regulating functionality of idiotype-bearing self-reactive T-cells. To explore this, in this study, 39 patients with progressive (chronic) multiple sclerosis (MS) were multiply immunized with autological polyclonal T-cell vaccines (TCVs). None of the TCV-treated patients experienced any significant side-effects during the entire follow-up period (2 years). T-Cell vaccination had no significant effects on T-cell sub-population contents in the blood of MS patients after 2 years of immunotherapy initiation. However, a substantial reduction in the frequency of CD4 þ and CD8 þ memory T-cells able to produce interferon (IFN)-c following activation were noted in the blood of TCV-treated patients. Moreover, significant and sustained reduction in plasma IFNc levels and concomitant increases in interleukin (IL)-4 levels were documented in these samples. The TCV-treated subjects, however, exhibited no significant changes in plasma IL-17 and IL-18. More importantly was a significant decline in proliferative T-cell responses to myelin antigens in the TCV-treated patients, indicating attenuation of myelin-specific T-cell activity. Collectively, the results suggest that polyclonal T-cell vaccination is safe to use, able to induce measurable, long-lasting, anti-inflammatory immune effects in patients with advanced MS. ARTICLE HISTORY

show abstract

A balance between tissue-destructive and tissue-protective immunities: A role of toll-like receptors in regulation of adaptive immunity

Cited by 36 publications

References 55 publications

Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes

Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes

Co-upregulation of Toll-like receptors 2 and 6 on peripheral blood cells in patients with obstructive sleep apnea

Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosis

Contact Info

Product

Resources

About